Astrazeneca (AZN) Long-Term Investments (2014 - 2026)

Astrazeneca's Long-Term Investments history runs 13 years deep, the most recent figure standing at $2.6 billion for Q2 2026.

• In Q2 2026, Long-Term Investments rose 40.58% year-over-year to $2.6 billion; the TTM figure through Jun 2026 stood at $2.6 billion (up 40.58% YoY), while the FY2025 annual figure was $2.2 billion, up 36.21% from the prior year.
• Long-Term Investments for Q2 2026 stood at $2.6 billion, up from $306.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $2.6 billion in Q2 2026, with the low at $53.0 million in Q3 2022.
• The 5-year median for Long-Term Investments is $267.0 million (2024), against an average of $638.3 million.
• Peak annual rise in Long-Term Investments reached 1444.93% in 2022, while the deepest fall reached 92.78% in 2022.
• Astrazeneca's Long-Term Investments stood at $1.1 billion in 2022, then slumped by 86.21% to $147.0 million in 2023, then jumped by 1010.2% to $1.6 billion in 2024, then soared by 36.21% to $2.2 billion in 2025, then grew by 17.81% to $2.6 billion in 2026.
• Business Quant data shows AZN's Long-Term Investments at $2.6 billion in Q2 2026, $306.0 million in Q1 2026, and $2.2 billion in Q4 2025.